Market Place
Sourcing Support
Atara Bio to Participate at the Stifel 2024 Healthcare Conference
13 Nov 2024 //
BUSINESSWIRE
Atara Bio Reports Q3 2024 Financials & Operational Updates
12 Nov 2024 //
BUSINESSWIRE
Atara Bio to Announce Q 32024 Financial Results on Nov 12, 2024
05 Nov 2024 //
BUSINESSWIRE
Atara Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
04 Oct 2024 //
BUSINESSWIRE
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Rule
06 Sep 2024 //
BUSINESSWIRE
Atara Biotherapeutics to Join H.C. Wainwright 26th Annual Investment Conference
04 Sep 2024 //
BUSINESSWIRE
Atara Reports Q2 2024 Results, Progress And Leadership Update
12 Aug 2024 //
BUSINESSWIRE
Atara Biotherapeutics To Participate In Canaccord Genuity Growth Conference
07 Aug 2024 //
BUSINESSWIRE
FDA Accepts Atara`s BLA For Tab-cel With Priority Review
17 Jul 2024 //
BUSINESSWIRE
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule
05 Jul 2024 //
BUSINESSWIRE
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
03 Jul 2024 //
BUSINESSWIRE
Atara Biotherapeutics’ Ebvallo™ Wins Prix Galien Award for Orphan/Rare Diseases
21 Jun 2024 //
BUSINESSWIRE
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
17 Jun 2024 //
BUSINESSWIRE
Atara Bio Reports Inducement Grant Per Nasdaq Rule
07 Jun 2024 //
BUSINESSWIRE
Atara Bio: Participating At Goldman Sachs Healthcare Conference
05 Jun 2024 //
BUSINESSWIRE
Atara Presents Preclinical ATA3219 CAR-T Data For Autoimmune Diseases
29 May 2024 //
BUSINESSWIRE
Atara Submits Tab-cel BLA For Transplant Lymphoproliferative Disease
20 May 2024 //
BUSINESSWIRE
Pierre Fabre announces the submission by Atara of Tabelecleucel (Tab-cel®)
20 May 2024 //
PR NEWSWIRE
Atara Bio Q1 2024 Financials, Operational Progress
09 May 2024 //
BUSINESSWIRE
Atara Reports Nasdaq Listing Rule Inducement Grant
03 May 2024 //
BUSINESSWIRE
Atara Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2024 //
BUSINESSWIRE
Atara Announces Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
BUSINESSWIRE
Atara Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219
29 Feb 2024 //
BUSINESSWIRE
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion
28 Feb 2024 //
BUSINESSWIRE
Atara Announces Submission of Investigational NDA for ATA3219
14 Feb 2024 //
BUSINESSWIRE
Atara and Pierre Fabre Announce Publication of Phase 3 ALLELE Tab-cel® Data
31 Jan 2024 //
BUSINESSWIRE
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones
08 Jan 2024 //
BUSINESSWIRE
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
08 Jan 2024 //
BUSINESSWIRE
Atara Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 //
BUSINESSWIRE
Atara Biotherapeutics to lay off 73 California employees by the end of the year
18 Dec 2023 //
ENDPTS
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431
11 Dec 2023 //
BUSINESSWIRE
Atara Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2023 //
BUSINESSWIRE
Atara to Participate at the 6th Annual Evercore ISI HealthCONx Conference
22 Nov 2023 //
BUSINESSWIRE
Atara Biotherapeutics To Participate at the Stifel Healthcare Conference
13 Nov 2023 //
BUSINESSWIRE
Atara`s stock sinks as MS cell therapy fails in phase 2
09 Nov 2023 //
FIERCE BIOTECH
Atara Biotherapeutics Announces Data from Phase 2 EMBOLD Trial of ATA188
08 Nov 2023 //
BUSINESSWIRE
Pierre Fabre commits up to $640M in T-cell deal with Atara
04 Nov 2023 //
FIERCE PHARMA
Atara Announces Expanded Global Tab-cel® Partnership with Pierre Fabre
01 Nov 2023 //
BUSINESSWIRE
Atara Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Oct 2023 //
BUSINESSWIRE
Atara Announces Plans to Submit Tab-cel BLA in Q2 2024
19 Sep 2023 //
BUSINESSWIRE
Atara Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Sep 2023 //
BUSINESSWIRE
Atara to Participate in Cell Therapies in Autoimmune Panel Discussion
31 Aug 2023 //
BUSINESSWIRE
Atara Announces Second Quarter 2023 Financial Results and Operational Progress
08 Aug 2023 //
BUSINESSWIRE
Atara Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Aug 2023 //
BUSINESSWIRE
Atara to Participate in the Canaccord Genuity 43rd Annual Growth Conference
31 Jul 2023 //
BUSINESSWIRE
Atara Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jul 2023 //
BUSINESSWIRE
Atara to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
07 Jun 2023 //
BUSINESSWIRE
Atara Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
05 Jun 2023 //
BUSINESSWIRE
Atara Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jun 2023 //
BUSINESSWIRE
Atara Biotherapeutics Announces 1Q 2023 FYR and Operational Progress
08 May 2023 //
BUSINESSWIRE
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule
05 May 2023 //
BUSINESSWIRE
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results
01 May 2023 //
BUSINESSWIRE
Atara to Participate in Cell Therapy Panel Discussion at Health Care Conference
01 Mar 2023 //
BUSINESSWIRE
Atara to Participate in the H.C. Wainwright Cell Therapy Conference
21 Feb 2023 //
BUSINESSWIRE
Atara Biotherapeutics Announces Q4 and Full Year 2022 Financial Results
08 Feb 2023 //
BUSINESSWIRE
Verily welcomes Atara Biotherapeutics veteran as new CFO
08 Feb 2023 //
ENDPTS
Atara Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Feb 2023 //
BUSINESSWIRE
Atara Biotherapeutics Ebvallo (tabelecleucel) Receives Approval in Europe
13 Jan 2023 //
FDA
Atara`s Ebvallo (tabelecleucel) Receives Approval in Europe
12 Jan 2023 //
EMA
HealthCare Royalty pays Atara $31M cash for a piece of cell therapy royalties
21 Dec 2022 //
ENDPTS
